Peter Ulvskjold steps in as interim CEO for the Atlas Antibodies Group
The Board of Atlas Antibodies and Nille Klaebel have together agreed that Nille will leave her position as the CEO of Atlas Antibodies Group. Peter Ulvskjold, currently CEO of the division Atlas Antibodies, will assume the role as interim CEO for the Group, as of February 1st.
Peter Ulvskjold has been with Atlas Antibodies since October 2022, and has previously held various leadership positions globally at ConvaTec and Novo Nordisk.
“The Board wants to thank Nille for her contribution to Atlas Antibodies during her tenure and we look forward to working with Peter and the rest of the team on the journey ahead” says Åsa Riisberg, Chairman of Atlas Antibodies.